Sugi Predict

Sugi Predict / Compounds / SCHEMBL2820898

SCHEMBL2820898

SCHEMBL2820898

CC(C)(C)OC(=O)N1CCCCC(O)C1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.56
▸ MEN1 O00255 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ EPHX1 P07099 1/20 0.50
▸ PREP P48147 2/20 0.48
▸ CHRM2 P08172 1/20 0.46
▸ CHRM1 P11229 1/20 0.46
▸ CHRM3 P20309 1/20 0.46
▸ USP2 O75604 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ RECQL P46063 1/20 0.43
▸ NR1H2 P55055 1/20 0.43
▸ PDE4B Q07343 1/20 0.43
▸ ABL1 P00519 1/20 0.42
▸ RIN1 Q13671 1/20 0.42
▸ USP30 Q70CQ3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22439376 1.00 HPGD (0.56) HPGDMEN1ALDH1A1MAPTKMT2A
SCHEMBL24438917 1.00 HPGD (0.56) HPGDMEN1ALDH1A1MAPTKMT2A
SCHEMBL31045798 0.98 HPGD (0.59) HPGDMEN1ALDH1A1MAPTKMT2A
SCHEMBL215146 0.95 MEN1 (0.56) HPGDMEN1ALDH1A1MAPTKMT2A
SCHEMBL190483 0.95 MEN1 (0.56) HPGDMEN1ALDH1A1MAPTKMT2A
SCHEMBL1068107 0.95 MEN1 (0.56) HPGDMEN1ALDH1A1MAPTKMT2A
SCHEMBL30862413 0.95 MEN1 (0.56) HPGDMEN1ALDH1A1MAPTKMT2A
Water SCHEMBL28231930 0.93 MEN1 (0.58) HPGDMEN1ALDH1A1MAPTKMT2A
Ammonia Solution, Strong SCHEMBL28243999 0.93 MEN1 (0.55) HPGDMEN1ALDH1A1MAPTKMT2A
Water SCHEMBL28231929 0.93 MEN1 (0.58) HPGDMEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710458-B1 IMMUNOPROTEASOME INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 — — EP disclosed
US-12447153-B2 HER2 mutation inhibitors PFIZER INC. (US) 2025-10-21 — — US disclosed
WO-2025123007-A1 RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-06-12 — — WO disclosed
US-12312370-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-05-27 — — US disclosed
US-20240199655-A1 Immunoproteasome Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-06-20 — — US disclosed
CN-111491938-B Immunoproteasome inhibitors 普林斯匹亚生物制药公司 2024-05-24 — — CN disclosed
EP-4359082-A1 HER2 MUTATION INHIBITORS Array BioPharma Inc. (US) 2024-05-01 — — EP disclosed
CN-117940425-A HER2 mutation inhibitors 阿雷生物药品公司 2024-04-26 — — CN disclosed
WO-2024063576-A1 NOVEL QUINAZOLINE COMPOUND AS KRAS INHIBITOR 일동제약(주) 2024-03-28 — — WO disclosed
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 — — US disclosed
WO-2012080990-A1 SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-06-21 — — WO disclosed
WO-2012080990-A1 SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-06-21 — — WO disclosed
EP-2007735-B1 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS GLAXO GROUP LTD (GB) 2010-10-27 — — EP disclosed
US-20090105225-A1 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists GLAXO GROUP LIMITED (GB) 2009-04-23 — — US disclosed
US-20080039444-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-02-14 — — US disclosed
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 — — US disclosed
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 — — US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 — — EP disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 — — US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199655-A1 Immunoproteasome Inhibitors PSMC2, PSMB7, PSMB2 HPGD 2490/4885MEN1 3171/4885ALDH1A1 3439/4885
US-12312370-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 HPGD 2490/4885MEN1 3171/4885ALDH1A1 3439/4885
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS HPGD 3375/4885MEN1 4852/4885ALDH1A1 4316/4885
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA HPGD 708/4885MEN1 2593/4885ALDH1A1 3541/4885
US-20080039444-A1 COMPOUNDS CMA1, MRGPRX2, HRH2 HPGD 118/4885MEN1 621/4885ALDH1A1 292/4885
US-20090105225-A1 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists HRH2, HRH3, HRH4 HPGD 191/4885MEN1 1160/4885ALDH1A1 1188/4885
US-12447153-B2 HER2 mutation inhibitors ERBB2, EGFR, ERBB3 HPGD 2596/4885MEN1 970/4885ALDH1A1 2320/4885
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 HPGD 339/4885MEN1 1993/4885ALDH1A1 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.